• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Zydus Life Sciences Acquires LiqMeds Group


New subsidiary specializes in development of oral liquid products.

Handshake in digital futuristic style. The concept of partnership, collaboration or teamwork. Vector illustration with light effect and neon. Image Credit: Adobe Stock Images/Lagunov

Image Credit: Adobe Stock Images/Lagunov

Zydus Lifesciences Limited announced that through Zydus Pharmaceuticals UK Limited, a wholly owned subsidiary, it has officially acquired LiqMeds Group, a company focused on the development, manufacturing, and supply of oral liquid products for the global market. Under terms of the acquisition, Zydus will pay an upfront amount of approximately $82.6 million with the potential for further yearly payments until 2026 depending on achievement of certain agreed milestones.

“We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities,” said Sharvil Patel, managing director, Zydus Life Sciences, in a company press release. “In line with our patient-centric approach, we believe that oral liquid formulations would help geriatric and paediatric patients, bringing in greater ease of convenience and therapy compliance.”

Reference: Zydus acquires UK based LiqMeds® Group. Zydus Life Sciences. October 31, 2023. Accessed October 31, 2023. https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-acquires-UK-based-LiqMeds--Group---31-10-2023.pdf

Related Videos
Related Content